Congo Expands Bundibugyo Testing as CEPI Backs 4 Vaccines With $63 Million
Updated
Updated · The New York Times · Jun 23
Congo Expands Bundibugyo Testing as CEPI Backs 4 Vaccines With $63 Million
2 articles · Updated · The New York Times · Jun 23
Summary
Same-day genetic testing is now operating at Congo’s outbreak epicenter and in nearby risk areas after early misidentification of the Bundibugyo virus and equipment shortages delayed case detection.
95% of close contacts must be traced to contain Ebola, but Congo is reaching only about 70% in recent days, with thousands still unmonitored in conflict zones and displacement camps.
Many samples still travel hours over dirt roads, electronic records are largely absent, and mistrust of isolation centers, funeral restrictions and misinformation is slowing testing and contact tracing.
WHO and partners are setting up clinical trials for vaccines and treatments, while CEPI is funding four Bundibugyo vaccine candidates and planning studies of MBP-134 and the oral antiviral obeldesivir.
15 million people live in the three affected Congolese provinces, and heavy informal cross-border movement leaves the region at high risk even as danger outside eastern Congo and nearby countries remains low.
Uganda is containing its Ebola outbreak while Congo struggles. What is the key to its success?
As a new Ebola strain rages, four vaccine candidates are in a race against time. Who will succeed?
With mistrust fueling the Ebola outbreak, can a new vaccine alone truly stop the spread?
2026 Bundibugyo Ebola Outbreak: Case Trends, Response Barriers, and Urgent Need for Vaccines
Overview
The Bundibugyo Ebola outbreak in Eastern DRC remains a major challenge due to ongoing humanitarian crises and decades of armed conflict, making the region highly vulnerable to disease spread. International concern has grown, with suspected cases reported in Israel after travel from the DRC. Response efforts are severely hampered by insecurity and logistical barriers, while the fragile health system struggles to cope. Despite these obstacles, improvements in testing capacity have been noted. The situation highlights the urgent need for coordinated global action, robust community engagement, and sustained investment to contain the outbreak and prevent further spread.